Curexo Inc. Overview
Curexo is South Korea's most established listed orthopedic surgical-robotics company. It sits inside the hy (formerly Korea Yakult) group, which has controlled it since 2011. Its main product is CUVIS-joint. This is an "active" robot that plans from CT scans and cuts bone automatically for total knee arthroplasty. It now also covers hips (CUVIS-joint THA). In March 2026 it received US FDA 510(k) clearance, and it holds EU CE MDR certification. Two other robots complete the line: CUVIS-spine, for pedicle-screw guidance, and Morning Walk, a gait-rehabilitation robot. Around the robots sit two cash-generating businesses. The first distributes orthopedic implants (Zimmer Biomet NexGen and Exactech shoulder). The second is a food-ingredient trading business that sells mainly to group-related customers hy and Paldo. FY2025 revenue reached a record KRW 74.5bn, and operating profit returned at KRW 2.4bn. Even so, Curexo remains a sub-scale player in a market led by Stryker, Zimmer Biomet, Smith+Nephew and J&J. Its differentiation rests on full automation, an open implant library, and pricing aimed at emerging markets.
The company's own description
Curexo's filings and investor materials describe three businesses. The medical robot business develops, makes and sells CUVIS-joint, CUVIS-spine and Morning Walk. The implant business distributes orthopedic implants. The trade business imports and sells food raw materials. (Sources: FY2025 business report summary via Valueline, 1Q26 update; Sangsangin Securities NDR deck, Mar 2025.)
The company describes CUVIS-joint as an active surgical robot. It plans from CT images and uses a six-axis vertical articulated arm to cut bone automatically. The robot is supplied to Korean general and specialty hospitals and exported to India, Malaysia, Indonesia, Japan and other markets. CUVIS-spine guides pedicle-screw insertion using C-arm and O-arm imaging and lowers radiation exposure.
In implants, Curexo runs the Korean master distributorship for Zimmer Biomet's NexGen knee system. In 2025 it added exclusive Korean rights to Exactech's shoulder implants.
The trade business imports ingredients such as chicory dietary fibre and crystalline fructose, used in fermented milk and ramen. Its principal customers are hy Co., Ltd. and Paldo Co., Ltd. (Source: FY2025 business report summary via Valueline.)
Business and revenue model
| Revenue stream | Model | Notes |
|---|---|---|
| Robot system sales | One-time capital equipment sale | Equipment estimated at KRW 200–500 million per unit (SK Securities, May 2025) |
| Robot consumables and service | Recurring, procedure-linked | Revenue comes from robot sales plus consumables; the company points to installed-base pull-through (THE VC analysis; CEO comments, Kukinews Sep 2022) |
| Distributor sales (exports) | Wholesale to local distributors | India (several distributors since 2025), Japan (Kyocera), Egypt (distributor contract 2026) |
| Implant distribution | Resale margin on third-party implants | Described as the most profitable segment by margin (The Bell / Money Today, Mar 2025) |
| Trade | Import-and-resell margin on food ingredients | Mostly sold to hy and Paldo. In FY2024, hy (KRW 10.7bn) and Paldo (KRW 14.9bn) were each disclosed as customers above 10% of sales (The Bell, Mar 2025) |
| Subscription or licensing | Not publicly disclosed as a material stream | — |
Value-chain position, customers and end-markets
Value chain. Curexo is an original equipment manufacturer for its own robots. It handles design, software (including AI-based surgical planning), assembly, regulatory work and training. It buys precision components externally. Examples include an actuator-supply MOU with SPG (Mar 2026) and earlier cost-reduction work with Neuromeca (Korea Investment & Securities, May 2024). In implants and trade, it is a distributor.
Customers.
-
Korean tertiary and specialty hospitals (robots, implants).
-
Overseas distributors and hospital groups (India, Japan, Southeast Asia, Egypt).
-
hy and Paldo (trade).
End-markets.
-
Orthopedic joint replacement (knee, hip)
-
Spine surgery
-
Neurological and stroke gait rehabilitation
-
Orthopedic implants (Korea)
-
Processed-food ingredients (Korea)
Independent characterization
Curexo is best described as a hybrid. It is an early-commercial surgical-robot developer, funded and stabilized by two low-growth but cash-generative distribution businesses.
Revenue quality: In FY2023, the robot segment was about 47% of sales and trade about 40% (NH Investment & Securities, Jan 2025). The robot segment fell to about 35% in FY2024 when the Indian channel broke down (Kiwoom, Jan 2026). In Q2 2026 it rose to about 53% (Butler, citing the H1 2026 report).
Profitability: It depends on robot volume. The robot segment lost about KRW 7bn in FY2024 and earned only KRW 1.3bn in FY2025 (Hankyung, Jul 2026). Group profitability therefore still leans on implants and trade.
Strategic thesis: The core bet is that a fully autonomous, open-platform knee and hip robot can win share in price-sensitive emerging markets (India, Southeast Asia, Middle East and Africa, Latin America) and in Japan. US and EU clearances in 2026 provide credibility but not yet revenue.
Strategy
Stated strategy (from the Feb and Jul 2026 shareholder letters)
1. Global diversification away from single-country dependence.
- The CEO described 2026 as a turning point away from a business built around one country (Newsway, Jul 2026).
2. Using US and EU approvals as a base for expansion into Europe, Latin America, the Middle East and Africa.
-
Country-by-country approvals.
-
Surgeon training.
-
Building clinical data.
-
Strengthening partnerships.
3. Widening indications and refreshing products.
-
CUVIS-joint THA (hip).
-
Knee 2.0.
-
Spine endoscopic navigation.
-
Morning Walk 3.0 (smaller, easier to use).
4. Next-generation AI-based surgical robots.
-
Medium-term technology leadership is the stated aim.
-
The brain-surgery robot is described as the next growth engine.
5. Financial target.
-
Record revenue in 2026, above FY2025's KRW 74.5bn.
-
Robot share of revenue above 60% (Finance Scope, Oct 2025).
6. Shareholder communication.
-
Regular shareholder letters (Feb and Jul 2026).
-
IR events (Q1 2026 results IR on 28 May 2026).
-
Articles updated for governance reforms (Sep 2026).
Strategic initiatives in the last 24 months
| Date | Initiative | Type |
|---|---|---|
| Late 2024 – 2025 | Ended Meril exclusivity in India; multi-distributor model with Shelby and BioRad | Channel restructuring |
| Oct 2024 – Aug 2025 | Indian subsidiary for consumables and service | Market infrastructure |
| Mar 2025 | Exactech shoulder implants, exclusive in Korea | Portfolio extension (implants) |
| Jun 2025 – Mar 2026 | US FDA 510(k) for CUVIS-joint, filed by Curexo itself | Regulatory |
| 2025–26 | EU CE MDR for CUVIS-joint | Regulatory |
| Feb 2026 | Indian CDSCO MD-15 import licence; Vietnam approval | Regulatory |
| Mar 2026 | SPG MOU for precision actuators (localization of parts, supply-chain resilience) | Supply chain |
| Apr 2026 | Egypt distributor agreement | Market entry (Africa) |
| Apr 2026 | Korea–India Business Partnership Forum, New Delhi | Market development |
| Sep 2026 | ISTA 2026 (Munich) showcase; European partner development | Market entry (EU) |
| Late 2026 (planned) | Start of brain-surgery robot development | R&D |
Cost programs: none announced with targets. Past cost initiatives include Neuromeca-based component cost reductions (2024).
Sustainability / ESG commitments: none published.
Management targets versus sell-side forecasts
| Item | Value | Source |
|---|---|---|
| 2026 revenue target | A record, above KRW 74.5bn (no number given) | Shareholder letter (Jul 2026) |
| 2026 robot share target | above 60% of revenue | Finance Scope (Oct 2025) |
| Daishin 2026E revenue / OP (KRW bn) | 101 / 8 | Finance Scope (Oct 2025) |
| Daishin 2027E revenue / OP (KRW bn) | 121 / 11 | Finance Scope (Oct 2025) |
| NH 2025E revenue / OP (KRW bn) | 85 / 3.1 (actual: 74.5 / 2.4) | BizWatch (Jan 2025) |
Products & Services
Medical Robot segment
CUVIS-joint (knee; model CJ150 in the US 510(k))
What it is: an active robot for total knee arthroplasty. The surgeon plans from a pre-operative CT scan; the robot tracks the bone optically and its six-axis arm cuts automatically.
Software: auto-segmentation, automatic implant sizing, and AI-based surgical planning trained on prior bone-surgery data (RYortho, 2020; Hankyung, Jul 2026). The planning software was co-developed with a Korean software firm (Dealsite, Dec 2019).
Open implant library: works with implants from multiple manufacturers. THINK Surgical's CEO highlighted this in the 2022 US distribution announcement.
Upgrade: "Knee 2.0" was presented at KIMES 2026 (Medigate, Mar 2026).
Positioning: the company describes it as the world's fifth commercialized system of its type (Kukinews, Sep 2022).
Target customers: orthopedic departments in tertiary and specialty hospitals; distributors and hospital chains in export markets.
Launch history: MFDS approval Jun 2020; first installation Nov 2020; FDA 510(k) clearance Mar 2026.
Regulatory footprint: Korea, India (CDSCO MD-15 import licence Feb 2026), Indonesia and Malaysia (2024), Russia (2023, per Korea Investment & Securities), Taiwan (Jan 2025), Japan (PMDA, Mar 2025), Vietnam (by Feb 2026), US (510(k) K252037, Mar 2026), EU (CE MDR, 2026).
Pricing: system pricing not publicly disclosed. SK Securities estimates KRW 200–500 million per unit. Consumables are sold per procedure.
Adoption: more than 5,000 cumulative procedures by Sep 2022. More than 4,000 cases were cited in the August 2022 THINK release.
CUVIS-joint THA (hip)
-
Extends CUVIS-joint to total hip arthroplasty, with CT/AI analysis of pelvic and femoral anatomy (Hankyung coverage, 2025–26).
-
MFDS approval in 2025. First Korean surgery reported Feb 2026.
-
Shown at KIMES 2026. Management positions it as the "knee to hip" step for Japan (Edaily, May 2026).
CUVIS-spine
-
A spine robot that guides the pedicle-screw trajectory under C-arm or O-arm imaging. The company says it reduces radiation exposure and surgical error.
-
An endoscopic navigation feature was presented at KIMES 2026.
Approvals: MFDS Dec 2019. FDA 510(k) K201569 (May 2021), K222698 (Oct 2022, Special) and K223558 (Jun 2023). Taiwan in late 2024.
Target customers: neurosurgery and orthopedic spine departments.
Morning Walk
-
An end-effector gait-rehabilitation robot for patients with lower-limb paralysis or gait impairment. Acquired with Hyundai Heavy Industries' medical robot division in 2017.
-
A propulsion (push-off) training system was shown at KIMES 2026.
Next generation: Morning Walk 3.0, focused on smaller size and ease of use, is in development (Hankyung, Jul 2026).
Reimbursement: expanded non-reimbursed (out-of-pocket) billing in Korea was cited as a demand driver (Korea IR Council, Nov 2022).
TSolution One / ROBODOC (THINK Surgical, distributed)
-
Curexo distributes THINK Surgical's active knee robot in Korea and Vietnam (THINK/Curexo release, Aug 2022).
-
ROBODOC was the first-generation system. Its assets came from ISS in 2007.
Legacy and other listed devices
-
Third-party databases also list ROBIN (a robot for needle-path guidance in CT-guided interventions) and Baidy (a device to assist labour) (Snowball Analytics).
-
Older profiles describe distribution of MRI, endoscopy and an "Endosector" breast-tissue device (EMIS).
-
They do not appear in 2025–26 investor materials.
Pipeline
Brain-surgery robot: development to start in late 2026, with a prototype targeted for around 2027 (CEO interview, Hankyung, Jul 2026).
Next-generation AI-assisted surgical robots: a medium-term goal in the Feb 2026 shareholder letter.
Multicentre clinical study: started in March 2026 with completion targeted within the year. The device involved is not specified in available coverage (JKN, Apr 2026).
Implant segment
| Product | Description | Status |
|---|---|---|
| Zimmer Biomet NexGen knee system | Total knee implant system; Curexo is the Korean master distributor | Ongoing (FY2025 business report summary) |
| Exactech shoulder implants | Shoulder arthroplasty; exclusive Korean distribution | Signed Mar 2025 (BizWatch) |
| Other implants | — | — |
Trade segment
| Product | End-use | Customers |
|---|---|---|
| Chicory dietary fibre | Fermented milk products | hy |
| Crystalline fructose | Fermented milk, foods | hy, Paldo |
| Ramen raw materials | Instant noodles | Paldo |
Source: FY2025 business report summary via Valueline. The trade business is sensitive to exchange rates, oil prices and overseas crop conditions.
Financial Narrative
Basis: consolidated K-IFRS (Korean International Financial Reporting Standards) unless noted. Sources: SK Securities (Feb 2024; Apr 2025; May 2025), Butler (DART summary), etfshopping.com (DART quarterlies), Medigate (Feb 2026), Valueline (DART balance sheet). Net income is attributable to owners of the parent.
Income statement — annual
Notes:
TTM metrics (Investing.com, Oct 2026): gross margin 34%, EBITDA KRW 6.03bn, EPS KRW 133.
FY2025 EPS (derived): about KRW 68 (KRW 2.8bn ÷ ~41.1m shares).
Dividends per share: zero in all years. The company does not pay dividends (Snowball; itooza).
Longer history (context)
Source: SK Securities (Feb 2024).
The large net losses in FY2017–FY2019, against small operating losses, point to non-operating charges. They are consistent with Curexo's former US subsidiary (THINK Surgical, called "TSI" in a 2018 company statement) and its later separation.
Quarterly income statement
Sources: etfshopping.com (DART periodic reports); Newsway (1Q26 OP of −KRW 0.913bn). 4Q25 is derived as FY2025 minus 9M2025.
1H26 revenue was KRW 39.7bn (+8.8% YoY versus KRW 36.5bn) and OP KRW 1.5bn. Trailing-twelve-month revenue at 2Q26 was KRW 77.7bn (derived; Investing.com shows KRW 77.74bn).
Balance sheet
Sources: SK Securities (Apr 2025) for current assets FY2020–FY2024 and long-term financial assets; Valueline (DART, consolidated) for FY2024–FY2025 cash, short-term financial assets and total assets.
Debt. The company's only disclosed financial debt is convertible bonds:
1st CB (2019): KRW 0.4bn; fully converted by Nov 2021.
2nd CB (May 2021): KRW 15bn; conversion price KRW 10,459; conversion window to April 2026; maturity May 2026.
3rd CB (Apr 2026): KRW 0.5bn; 4% yield to maturity; conversion price KRW 16,039; no refixing.
Cash flow
The company paid no dividends and conducted no buybacks; treasury shares were 0.00% (SK Securities, May 2025; Butler). Cash rose from KRW 13.9bn at FY2024 year-end to KRW 18.7bn at FY2025 year-end, then fell to KRW 16.7bn at 30 June 2026.
Ratios
FY2021–FY2024 from SK Securities (Apr 2025). FY2025 derived as KRW 2.8bn ÷ about KRW 97bn average equity (approximate).
Commentary on trends and drivers
FY2021–FY2023: robot-led scale-up. Revenue grew from KRW 42.8bn to KRW 72.9bn.
-
The main driver was CUVIS-joint exports to India under the Meril agreement, plus Korean installations.
-
By FY2023, Meril alone accounted for about 57% of robot revenue (KRW 19.5bn) per IB Tomato. SK Securities gives 62.5%; the base of that figure is truncated in the source. Note the discrepancy.
-
Operating income stayed at break-even (KRW 1.1bn in both FY2022 and FY2023) as R&D and regulatory spending rose.
FY2024: the inflection. Two shocks hit at once.
-
Korea's physician (resident) walkout reduced domestic procedure volumes and robot purchases. 1Q24 unit sales fell to 12 from 23 a year earlier (Korea Investment & Securities).
-
Meril developed its own robot (MISSO) and cut imports.
-
Robot revenue roughly halved, group revenue fell 23.8% and OP dropped to −KRW 5.8bn. The robot segment's loss of about KRW 7bn was the largest on record (The Bell).
FY2025: recovery and diversification. Revenue grew 34.2% to a record KRW 74.5bn.
-
Robot revenue grew 88%. Curexo added Indian distributors, Meril returned as a buyer, and new markets opened (Japan, Taiwan, Malaysia, Indonesia, later Vietnam).
-
All three segments were profitable, but group OP margin was only 3.2%. Spending on the FDA trial and filing weighed on SG&A (Sangsangin, Dec 2025).
-
Actual revenue of KRW 74.5bn fell short of sell-side expectations of KRW 80–90bn (NH KRW 85bn; Sangsangin KRW 80–90bn optimistic case).
1H2026: volatile but positive.
-
1Q26 revenue fell 18.3% and OP turned negative, because robot revenue dropped 43% on the timing of shipments.
-
2Q26 revenue reached a record quarterly KRW 23.6bn (+40.6% YoY), with robot revenue doubling to KRW 12.6bn and robot OP of KRW 2.2bn.
-
The lumpiness shows that a few multi-unit distributor orders still drive quarterly results.
Balance sheet. Assets of about KRW 111bn are mostly current. Equity of about KRW 101bn is funded largely by past equity raises and CB conversions rather than retained earnings. Leverage is negligible, so financing risk is low. Spending on regulatory approvals, US/EU launches and brain-robot R&D could, however, absorb the KRW 17–19bn cash balance within a few years if profitability does not scale.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key products / partners |
|---|---|---|
Medical Robot (의료로봇사업) | Design, manufacture, sale and service of surgical and rehabilitation robots, plus consumables; distribution of THINK Surgical TSolution One | CUVIS-joint (TKA/THA), CUVIS-spine, Morning Walk, TSolution One / ROBODOC |
Implant (임플란트사업) | Korean distribution of orthopedic joint implants | Zimmer Biomet NexGen (Korean master distributor); Exactech shoulder (exclusive since 2025) |
Trade (무역사업) | Import and sale of food raw materials | Chicory fibre, crystalline fructose, fermented-milk and ramen inputs. Customers: hy, Paldo |
Revenue by Segment
| Segment | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Medical Robot revenue (KRW Bn) | 6.3 | 10.5 | — | 34.2 | 19.4 | 36.5 |
Implant revenue (KRW Bn) | — | — | — | 9.5 | — | — |
Trade revenue (KRW Bn) | — | — | — | 29.2 | — | — |
Total revenue (KRW Bn) | 39.3 | 42.8 | 65.0 | 72.9 | 55.5 | 74.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Overview — Medical Robot revenue
| Segment | 1Q24 | 1Q25 | 1H25 | 3Q25 | 9M25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|---|
Medical Robot revenue (KRW Bn) | 5.0 | 10.1 | 16.4 | 8.4 | 24.8 | 5.7 | 12.6 |
Implant revenue (KRW Bn) | 2.6 | — | 5.9 | — | 8.7 | — | 3.3 |
Trade revenue (KRW Bn) | 6.4 | — | 14.3 | — | 20.2 | — | 7.8 |
Total revenue (KRW Bn) | 13.9 | 19.7 | 36.5 | 17.2 | 53.7 | 16.1 | 23.6 |
Results by Segment and Segment Margins & Growth (%)
| Segment metric | FY2024 | FY2025 | 2Q26 |
|---|---|---|---|
Medical Robot operating income (KRW Bn) | -7.1 | 1.3 | 2.2 |
Medical Robot operating margin (%) | -36.6 | 3.6 | 17.5 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Medical Robot share of revenue (%) | 46.9 | 34.9 | 49.0 |
Medical Robot revenue growth YoY (%) | — | -43.3 | 88.0 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 42.8 | 65.0 | 72.9 | 55.5 | 74.5 |
Revenue growth YoY (%) | 8.9 | 51.9 | 12.1 | -23.8 | 34.2 |
Operating income (KRW Bn) | -1.8 | 1.1 | 1.1 | -5.8 | 2.4 |
Net income attributable (KRW Bn) | -2.3 | -3.0 | -4.9 | -8.8 | 2.8 |
Operating margin (%) | -4.2 | 1.7 | 1.5 | -10.5 | 3.2 |
Net margin (%) | -5.4 | -4.6 | -6.7 | -15.9 | 3.8 |
EPS basic (KRW) | -70 | -84 | -120 | -213 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|
Revenue (KRW Bn) | 33.5 | 33.9 | 34.4 | 39.3 |
Operating income (KRW Bn) | 0.6 | -3.8 | -4.3 | 0.7 |
Net income attributable (KRW Bn) | -16.9 | -29.4 | -25.9 | 0.4 |
EPS (KRW) | -583 | -898 | -777 | 12 |
Valuation Snapshot
| Metric | Value | Method |
|---|---|---|
4-year revenue CAGR, FY2021–FY2025 (%) | 14.9 | (74.5 / 42.8)^(1/4) − 1 |
5-year revenue CAGR, FY2020–FY2025 (%) | 13.6 | (74.5 / 39.3)^(1/5) − 1 |
Financial Analysis
| Metric | 3Q24 | 4Q24 | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 13.2 | 14.8 | 19.7 | 16.8 | 17.2 | 20.8 | 16.1 | 23.6 |
Operating income (KRW Bn) | -1.4 | -1.5 | 0.8 | -0.2 | 0.3 | 1.5 | -0.9 | 2.4 |
Net income (KRW Bn) | -1.6 | -5.4 | 1.1 | -0.9 | 0.8 | 1.8 | 0.5 | 2.5 |
Balance Sheet
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Current assets (KRW Bn) | 39 | 50 | 76 | 91 | 87.9 | 87.1 |
Cash and cash equivalents (KRW Bn) | — | — | — | — | 13.9 | 18.7 |
Short-term financial assets (KRW Bn) | — | — | — | — | 0.4 | 1.8 |
Long-term financial assets (KRW Bn) | 0 | 3 | 16 | 8 | 4 | — |
Total assets (KRW Bn) | — | — | — | — | 102.6 | 101.1 |
Financial Analysis — Total assets
| Metric (as of 30 Jun 2026) | Value | Source / method |
|---|---|---|
Total assets (KRW Bn) | 111.4 | Valueline (DART) |
Current assets (KRW Bn) | 97.1 | Valueline (DART) |
Cash and equivalents (KRW Bn) | 16.7 | Valueline (DART) |
Short-term financial assets (KRW Bn) | 1.2 | Valueline (DART) |
Shareholders' equity (KRW Bn) | ~100.9 | Derived: book value per share KRW 2,444.88 (Investing.com) × 41.26m shares |
Total liabilities (KRW Bn) | ~10.5 | Derived: total assets − equity |
Net cash, 3Q24 (KRW Bn) | 36.7 | NH Investment & Securities (Jan 2025) |
Debt-to-equity (liabilities/equity), 3Q24 (%) | 9 | NH Investment & Securities (Jan 2025) |
Current ratio, early 2026 | above 20x (current ratio "in the 2,000% range") | IB Tomato (Apr 2026) |
Returns & Leverage Ratios (%)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | -5.3 | -4.9 | -5.3 | -9.0 | 2.9 |
Financial Analysis — ROE, TTM
| Ratio (latest available) | Value | Source |
|---|---|---|
ROE, TTM (%) | 5.7 | Investing.com (Oct 2026). Valueline showed 5.46% (Aug 2026); itooza 2.17% (mid-2026, earlier TTM base) |
ROA, TTM (%) | 5.1 | Investing.com |
Current ratio | above 20x | IB Tomato (Apr 2026) |
Liabilities/equity | about 10% | Derived (Jun 2026) |
Net debt / EBITDA | Negative (net cash) | Derived |
Interest coverage | Not meaningful (negligible interest-bearing debt) | — |
Asset turnover, TTM | about 0.7x | Derived: KRW 77.7bn ÷ ~KRW 106bn average assets |
Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Robot export revenue (KRW Bn) | — | 10.3 | 27.2 |
India (Meril) robot revenue (KRW Bn) | 19.5 | — | — |
Geographic Revenue
| Indicator | Value | Source |
|---|---|---|
Overseas share of robot unit sales (9M2022) | 47.5% | Hana Securities (Jan 2023) |
Year overseas robot unit sales first exceeded domestic | 2022 | Company statement, Kukinews (Feb 2025) |
Overseas share of robot revenue (FY2024) | about 60%. SK's statement on the overseas share is truncated, but it is most consistent with the robot segment, because trade revenue is domestic. | SK Securities (May 2025) |
India robot exports, 3Q25 / 4Q25 (estimates) | KRW 6bn+ / about KRW 7bn | Sangsangin (Dec 2025) |
India supply contract (2026) | KRW 8.5bn | Newsway (Jul 2026) |
Markets
| Market | Status | Trend |
|---|---|---|
Korea | Robots, implants and all trade revenue | Robot demand hurt in 2024 by the physician walkout. Implants and trade stable. |
India | Largest export market. Subsidiary consolidated from 1Q25; MD-15 import licence Feb 2026; several distributors (Meril, Shelby, BioRad) | Collapsed in 2024; recovered in 2025; new KRW 8.5bn contract in 2026 |
Japan | Kyocera exclusive distributor; PMDA approval Mar 2025 | Early ramp. Japan's knee/hip robot market was about 150 units in 2023, growing 30%+ a year (Edaily, May 2026) |
Taiwan, Malaysia, Indonesia, Vietnam, Myanmar | Approvals 2024–26; first commercial sales 2025–26 | Growing from a small base |
Egypt / Africa | Distributor supply contract Apr 2026 | New |
United States | 510(k) Mar 2026. | No sales disclosed yet. First US revenue timing not given (Newsway, Jul 2026). |
European Union | CE MDR 2026; ISTA Munich showcase Sep 2026 | Kiwoom (Jan 2026) forecast 5–10 units in Europe in 2026. Italy flagged as a partner market. |
Share Price History
| Date | Price | Market cap (KRW Bn) | Source |
|---|---|---|---|
2 Jul 2021 | 9,540 | 319 | Yuanta |
13 Feb 2024 | 15,550 | 637 | SK Securities (52-week high then KRW 24,400) |
31 Mar 2025 | 7,870 | 328 | SK Securities |
29 May 2025 | 9,500 | 389 | SK Securities |
30 Oct 2025 | 10,720 | — | littlebproject |
21 Jan 2026 | 17,060 | 701 | Kiwoom |
21 Apr 2026 | 15,690 | — | JKN |
26 Jun 2026 | 8,580 | 354 | Valueline |
22 Jul 2026 | 8,000 | — | Asia Economy |
2 Oct 2026 | 8,780 | 362 | Investing.com |
6 Oct 2026 | 9,000 | 371 | Kokstock |
Valuation Multiples
| Multiple | Curexo | Source / method |
|---|---|---|
P/E (TTM) | about 60x | Investing.com (60.4x) |
P/E (forward) | about 48–51x | Snowball (48.1x); Butler (51.0x) |
P/B | about 3.6x | Investing.com |
EV/EBITDA (TTM) | about 56x | Investing.com (55.9x) |
EV/Sales (TTM) | about 4.3x | Derived: EV of about KRW 337bn (55.9 × KRW 6.03bn EBITDA) ÷ KRW 77.7bn revenue |
Metric | FY2021 | FY2022 |
Year-end P/B (x) | 1.4 | 1.2 |
Analyst Conclusions
Guidance and expectations
Management guidance.
-
Record 2026 revenue (above KRW 74.5bn).
-
Robot share of revenue above 60%.
-
Expansion into the US, EU, Latin America, Middle East and Africa.
-
Brain-robot development to start.
What the second half needs to deliver.
-
1H26 revenue was KRW 39.7bn, so 2H26 must exceed KRW 34.8bn to set a record. That is a run-rate of about KRW 17.4bn a quarter, below 2Q26's KRW 23.6bn.
-
The record-revenue target therefore looks achievable on current trends.
-
Daishin's KRW 101bn forecast would require about KRW 61bn in 2H26, which looks stretched.
-
No formal consensus is available.
Bull case
-
Approvals start converting into sales. FDA (Mar 2026), CE MDR (2026) and PMDA (2025) open developed markets that value autonomous, open-platform robots. A first US or EU order would rerate the stock against peers.
-
Operating leverage in the robot segment is now visible. Robot revenue of KRW 12.6bn in 2Q26 produced KRW 2.2bn OP (about 17% margin). If annual robot revenue exceeds KRW 50bn, group margins could move into high single digits.
-
More robots and more procedures per robot. Diversification (India multi-distributor model, Japan, ASEAN, Egypt, Vietnam) reduces single-partner risk. Hip (THA) adds procedures per installed robot, lifting consumables revenue.
Bear case
-
Execution has been uneven. FY2025 missed sell-side forecasts by 12–20%. 1Q26 robot revenue fell 43%. No confirmed US or EU orders yet. At a P/E of about 60x and EV/EBITDA of about 56x, the stock prices in success that has not been demonstrated.
-
Structural competitive disadvantage. Implant-bundled incumbents control surgeon relationships. The Meril precedent shows that partners can become competitors. In the US, the related-party THINK channel adds complexity.
-
Margins remain thin. The FY2025 OP margin was 3.2% even in a record year. US and EU commercialization, Morning Walk 3.0 and brain-robot R&D will raise costs before revenue arrives.
Catalysts and monitorables (next 12 months)
-
3Q26 results (expected 16 Nov 2026): robot revenue and profitability; progress toward the record-revenue target.
-
First US commercial placement and the US channel structure (THINK Surgical's role).
-
First European placements following CE MDR and ISTA 2026.
-
Japan unit ramp via Kyocera; THA launch in Japan.
-
Deliveries under the KRW 8.5bn Indian contract; Indian market share against MISSO, CORI and VELYS.
-
Start of brain-robot development (late 2026) and readout of the 2026 multicentre study.
-
Conversion and dilution from the CBs; hy stake changes; related-party developments.
-
FY2026 annual report (March 2027): R&D spend, segment margins, geographic disclosure.
Analyst verdict
Curexo has turned its technology into a commercially viable regional business. Whether it can build a globally relevant orthopedic robotics franchise remains unproven.
The evidence for progress is real. FY2025 revenue reached a record KRW 74.5bn, robot-segment revenue nearly doubled, and all three segments were profitable. 2Q26 delivered a record quarter, and the robot segment's 17% operating margin showed what volume can do for profitability. The company now holds clearances from the US FDA, EU (MDR), Japan, India and much of Southeast Asia. That regulatory breadth is unusual for a Korean robotics company with fewer than 110 employees. Its fully autonomous, open-implant approach gives distributors and implant makers without their own robot a credible alternative to closed ecosystems. The balance sheet is close to debt-free, so near-term financing risk is low.
The weaknesses are just as concrete. Revenue remains lumpy and distributor-driven: 1Q26 robot revenue fell 43% YoY. Group margins were 3% even in a record year. Roughly half of revenue still comes from distributing other companies' implants and trading food ingredients for group-related customers. The 2024 Meril episode showed how quickly an emerging-market partner can become a competitor. Developed-market approvals have not yet produced orders, and management has given no dates for first US sales.
At about KRW 9,000, the market capitalization of about KRW 371bn implies roughly 60x trailing earnings and 4–5x sales. That valuation already discounts substantial robot growth. It is far below the January 2026 peak (above KRW 700bn), which shows how sentiment swings with each quarter.
The balanced conclusion is that this is a high-optionality, execution-dependent small cap. The decisive evidence over the next 12–18 months will be:
-
confirmed US and European placements;
-
consistent quarterly robot revenue above KRW 10bn;
-
stable or rising robot-segment margins.
Until those appear, the investment case rests more on regulatory potential than on demonstrated global commercial traction.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / background | Source |
|---|---|---|---|
Lee Jae-jun (이재준) | CEO and Representative Director | CEO since 2012. Previously a director at Korea Yakult; moved to Curexo after the 2011 acquisition. | Hankyung (Jul 2026); NDR deck (Mar 2025) |
Kim Seong-myeon (김성면) | Managing Director, Chief Strategy Officer | Former CEO of Handol Medical | NDR deck (Mar 2025) |
Moon Jeon-il (문전일) | Outside director | CEO of Robocare | NDR deck (Mar 2025) |
Noh Kyung-oh (노경오) | Independent director and audit committee member | Born 1964; re-elected 17 Sep 2026 for a three-year term | Digital Today (Sep 2026) |
Jay Koh | Regulatory contact for FDA submissions | Title not disclosed | FDA K252037 |
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
hy Co., Ltd. (formerly Korea Yakult) | 30.94% | 2025 (SK Securities, Apr/May 2025) |
hy, earlier trend | 36.61% (with one related party, Jul 2021) → 35.47% (late 2021) → 30.5% (Jul 2022) → 30.71% (Feb 2024) | Yuanta; Dealsite; Korea IR Council; SK Securities |
Minority shareholders | 63.5% (59,869 holders) | End-FY2025 annual report (etfshopping.com) |
Treasury shares | 0.00% | SK Securities |
Foreign ownership | 0.72% | — |
Top 10 institutional holders | Not publicly disclosed (no institution above 5% identified) | — |
Insider ownership (excluding hy) | — | Butler (DART list) |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Platform | Notes |
|---|---|---|---|
Knee/hip robotics | Stryker | Mako | Global leader in robotic joint replacement; haptic, closed implant system |
Knee/hip robotics | Zimmer Biomet | ROSA Knee/Hip | Also Curexo's implant supplier in Korea, which creates a partner/competitor tension |
Knee/hip robotics | Smith+Nephew | CORI | Image-free handheld system. With CUVIS-joint, made up more than half of Indian joint-robot installations as of Sep 2024 (third-party LinkedIn commentary; low reliability) |
Knee/hip robotics | Johnson & Johnson MedTech (DePuy Synthes) | VELYS | Strong presence in India and Asia |
Knee/hip robotics | Meril (Micro Life Sciences, India) | MISSO | Former Curexo distributor turned competitor. Reportedly under 8.6% of Indian installations by Sep 2024. Meril valued at an enterprise value of USD 6.6bn (ADIA deal, Jul 2025). |
Knee/hip robotics | THINK Surgical (US; hy affiliate) | TSolution One / TMINI | Related party; partner and potential competitor |
Spine robotics | Medtronic | Mazor | Spine-robot leader |
Spine robotics | Globus Medical | ExcelsiusGPS | Spine-robot leader |
Spine/neuro robotics | Koh Young Technology (Korea) | Brain-surgery robot | Korean peer; relevant to Curexo's planned brain robot |
Rehabilitation robotics | Hocoma (DIH) | Lokomat | Exoskeleton-type gait trainer |
Rehabilitation robotics | Angel Robotics (Korea) | Wearable exoskeletons | Domestic rehab competitor |
General surgical robotics context | Intuitive Surgical | da Vinci | Holds over 80% of the global surgical-robot market (Kukinews, Feb 2025); not a direct orthopedic competitor |
Peer Comparison FY2024
| Company | Latest FY revenue | YoY growth | Operating margin | Source |
|---|---|---|---|---|
Curexo | KRW 74.5bn (FY2025) | +34.2% | 3.2% | DART summaries; SK Securities |
Stryker | USD 22.6bn (FY2024) | about +10% | — | — |
Zimmer Biomet | USD 7.7bn (FY2024) | about +4% | — | — |
Smith+Nephew | USD 5.8bn (FY2024) | about +5% | — | — |
Recent Developments
Not found in the period: * layoffs, guidance withdrawals, litigation or regulatory actions.



